vs
Astrana Health, Inc.（ASTH）与科睿唯安（CLVT）财务数据对比。点击上方公司名可切换其他公司
Astrana Health, Inc.的季度营收约是科睿唯安的1.6倍（$950.5M vs $585.5M），Astrana Health, Inc.净利率更高（0.7% vs -6.9%，领先7.6%），Astrana Health, Inc.同比增速更快（42.9% vs -1.4%），科睿唯安自由现金流更多（$78.9M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -5.1%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
ASTH vs CLVT — 直观对比
营收规模更大
ASTH
是对方的1.6倍
$585.5M
营收增速更快
ASTH
高出44.3%
-1.4%
净利率更高
ASTH
高出7.6%
-6.9%
自由现金流更多
CLVT
多$84.8M
$-6.0M
两年增速更快
ASTH
近两年复合增速
-5.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $585.5M |
| 净利润 | $6.6M | $-40.2M |
| 毛利率 | — | 67.2% |
| 营业利润率 | 1.9% | 5.2% |
| 净利率 | 0.7% | -6.9% |
| 营收同比 | 42.9% | -1.4% |
| 净利润同比 | 184.4% | 61.3% |
| 每股收益（稀释后） | $0.12 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHCLVT
| Q1 26 | — | $585.5M | ||
| Q4 25 | $950.5M | $617.0M | ||
| Q3 25 | $956.0M | $623.1M | ||
| Q2 25 | $654.8M | $621.4M | ||
| Q1 25 | $620.4M | $593.7M | ||
| Q4 24 | $665.2M | $663.0M | ||
| Q3 24 | $478.7M | $622.2M | ||
| Q2 24 | $486.3M | $650.3M |
净利润ASTHCLVT
| Q1 26 | — | $-40.2M | ||
| Q4 25 | $6.6M | $3.1M | ||
| Q3 25 | $373.0K | $-28.3M | ||
| Q2 25 | $9.4M | $-72.0M | ||
| Q1 25 | $6.7M | $-103.9M | ||
| Q4 24 | $-7.8M | $-191.8M | ||
| Q3 24 | $16.1M | $-65.6M | ||
| Q2 24 | $19.2M | $-304.3M |
毛利率ASTHCLVT
| Q1 26 | — | 67.2% | ||
| Q4 25 | — | 66.8% | ||
| Q3 25 | — | 65.0% | ||
| Q2 25 | — | 67.2% | ||
| Q1 25 | — | 65.1% | ||
| Q4 24 | — | 65.7% | ||
| Q3 24 | — | 66.2% | ||
| Q2 24 | — | 67.2% |
营业利润率ASTHCLVT
| Q1 26 | — | 5.2% | ||
| Q4 25 | 1.9% | 6.7% | ||
| Q3 25 | 2.0% | 7.1% | ||
| Q2 25 | 3.1% | 1.1% | ||
| Q1 25 | 3.3% | -3.5% | ||
| Q4 24 | 0.1% | -9.4% | ||
| Q3 24 | 5.9% | 3.5% | ||
| Q2 24 | 6.2% | -36.9% |
净利率ASTHCLVT
| Q1 26 | — | -6.9% | ||
| Q4 25 | 0.7% | 0.5% | ||
| Q3 25 | 0.0% | -4.5% | ||
| Q2 25 | 1.4% | -11.6% | ||
| Q1 25 | 1.1% | -17.5% | ||
| Q4 24 | -1.2% | -28.9% | ||
| Q3 24 | 3.4% | -10.5% | ||
| Q2 24 | 3.9% | -46.8% |
每股收益（稀释后）ASTHCLVT
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.12 | $0.00 | ||
| Q3 25 | $0.01 | $-0.04 | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.14 | $-0.15 | ||
| Q4 24 | $-0.14 | $-0.27 | ||
| Q3 24 | $0.33 | $-0.09 | ||
| Q2 24 | $0.40 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | — |
| 总债务越低越好 | — | $4.3B |
| 股东权益账面价值 | $779.3M | $4.8B |
| 总资产 | $2.2B | $10.9B |
| 负债/权益比越低杠杆越低 | — | 0.89× |
8季度趋势，按日历期对齐
现金及短期投资ASTHCLVT
| Q1 26 | — | — | ||
| Q4 25 | $429.5M | $329.2M | ||
| Q3 25 | $463.4M | $318.7M | ||
| Q2 25 | $342.1M | $362.6M | ||
| Q1 25 | $260.9M | $354.0M | ||
| Q4 24 | $290.8M | $295.2M | ||
| Q3 24 | $350.3M | $388.5M | ||
| Q2 24 | $327.7M | $376.4M |
总债务ASTHCLVT
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.6B |
股东权益ASTHCLVT
| Q1 26 | — | $4.8B | ||
| Q4 25 | $779.3M | $4.8B | ||
| Q3 25 | $775.5M | $4.9B | ||
| Q2 25 | $765.5M | $5.0B | ||
| Q1 25 | $745.4M | $5.0B | ||
| Q4 24 | $712.7M | $5.1B | ||
| Q3 24 | $704.6M | $5.5B | ||
| Q2 24 | $678.9M | $5.6B |
总资产ASTHCLVT
| Q1 26 | — | $10.9B | ||
| Q4 25 | $2.2B | $11.1B | ||
| Q3 25 | $2.2B | $11.2B | ||
| Q2 25 | $1.4B | $11.4B | ||
| Q1 25 | $1.3B | $11.5B | ||
| Q4 24 | $1.4B | $11.5B | ||
| Q3 24 | $1.3B | $12.0B | ||
| Q2 24 | $1.3B | $12.1B |
负债/权益比ASTHCLVT
| Q1 26 | — | 0.89× | ||
| Q4 25 | — | 0.89× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $134.7M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $78.9M |
| 自由现金流率自由现金流/营收 | -0.6% | 13.5% |
| 资本支出强度资本支出/营收 | 0.3% | 9.5% |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | $333.9M |
8季度趋势，按日历期对齐
经营现金流ASTHCLVT
| Q1 26 | — | $134.7M | ||
| Q4 25 | $-2.9M | $159.9M | ||
| Q3 25 | $10.0M | $181.1M | ||
| Q2 25 | $90.9M | $116.3M | ||
| Q1 25 | $16.6M | $171.2M | ||
| Q4 24 | $-10.9M | $141.3M | ||
| Q3 24 | $34.0M | $202.9M | ||
| Q2 24 | $23.2M | $126.2M |
自由现金流ASTHCLVT
| Q1 26 | — | $78.9M | ||
| Q4 25 | $-6.0M | $89.2M | ||
| Q3 25 | $7.4M | $115.5M | ||
| Q2 25 | $89.5M | $50.3M | ||
| Q1 25 | $13.6M | $110.3M | ||
| Q4 24 | $-13.5M | $59.1M | ||
| Q3 24 | $31.7M | $126.3M | ||
| Q2 24 | $20.4M | $60.3M |
自由现金流率ASTHCLVT
| Q1 26 | — | 13.5% | ||
| Q4 25 | -0.6% | 14.5% | ||
| Q3 25 | 0.8% | 18.5% | ||
| Q2 25 | 13.7% | 8.1% | ||
| Q1 25 | 2.2% | 18.6% | ||
| Q4 24 | -2.0% | 8.9% | ||
| Q3 24 | 6.6% | 20.3% | ||
| Q2 24 | 4.2% | 9.3% |
资本支出强度ASTHCLVT
| Q1 26 | — | 9.5% | ||
| Q4 25 | 0.3% | 11.5% | ||
| Q3 25 | 0.3% | 10.5% | ||
| Q2 25 | 0.2% | 10.6% | ||
| Q1 25 | 0.5% | 10.3% | ||
| Q4 24 | 0.4% | 12.4% | ||
| Q3 24 | 0.5% | 12.3% | ||
| Q2 24 | 0.6% | 10.1% |
现金转化率ASTHCLVT
| Q1 26 | — | — | ||
| Q4 25 | -0.44× | 51.58× | ||
| Q3 25 | 26.69× | — | ||
| Q2 25 | 9.65× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
